Index by Country/Area

A

Argentina, 77, 135, 177, 210 Australia, 61, 62, 70, 77–78, 113, 120, 121, 135, 158, 170, 171–172, 177, 185, 200, 210, 212, 236 Austria, 78, 111, 113

В

Bangladesh, 78, 172
Barbados, 78, 197
Belgium, 78, 121
Benin, 78
Botswana, 78
Brazil, 19, 44, 78–80, 121, 135, 158, 160, 172, 177, 197, 231, 256
Bulgaria, 80, 135
Burkina Faso, 80

C

Cambodia, 80-81

112, 113, 120, 121-122, 135-136, 151, 158, 161, 170, 172, 177-178, 183, 185, 191-192, 200, 202, 212-213, 236, 247, 256 Central African Republic, 81 Central Europe, 52–53 Chile, 14, 81–82, 136, 172, 178, 197–198 China, 14, 82-83, 111, 112, 113, 122-123, 136–137, 157, 164, 170–171, 172, 176, 184, 186, 197–198, 213 Colombia, 83, 184 Cook Islands, 83 Costa Rica, 83, 123, 137 Côte d'Ivoire, 83 Croatia, 15, 184-185, 236 Czech Republic, 83, 110, 113, 123, 198, 235

Canada, 15, 31, 32, 61, 62, 65, 70-71, 81,

D

Democratic Republic of Congo, 83 Denmark, 61, 83, 123, 137, 157, 171, 235, 243 Dominican Republic, 19, 83, 231

E

Ecuador, 83 Egypt, 53, 83–84, 112, 213 England, 71, 111, 112, 159, 176 see also United Kingdom Ethiopia, 84

F

Finland, 65, 71, 84, 123, 236 France, 84, 123, 137, 160, 186, 192, 203

G

Gabon, 85 The Gambia, 85 Georgia, 85 Germany, 49, 85, 113, 123–124, 137–138, 172–173, 178, 198, 213–214 Ghana, 44, 85, 138, 250 Greece, 86, 138 Guatemala, 86, 138

н

Haiti, 86 Honduras, 86, Hungary, 86

Iceland, 65, 86
India, 14, 19, 53, 62, 86–87, 121, 124, 133, 135, 138–139, 159, 198–199, 214–215, 231, 247
Indonesia, 19, 87, 139–140, 231, 256–257
Iran, 87
Ireland, 12, 87, 121
Israel, 48, 53, 87–88, 111, 124, 151–152, 158, 171, 178, 200, 202, 237
Italy, 48–49, 59–60, 62, 65, 66, 69, 71, 88–89, 112–113, 124, 140, 178, 192, 199, 215–216, 257

J

Jamaica, 89, 124–125, 140 Japan, 49, 53, 60, 89, 111, 112, 113, 125, 140, 169, 175, 178, 199, 216, 192, 236 Jordan, 89

Κ

Kazakhstan, 126 Kenya, 27, 89–90, 131, 134, 14, 228, 250 Korea, 90–91, 113, 178, 216–217 Kuwait, 140

L

Laos, 91 Lebanon, 53, 91 Liberia, 91

M

Madagascar, 91, 178
Malawi, 91–92, 125, 134, 140, 173
Malaysia, 92, 135, 140–141
Mali, 29, 92
Mauritius, 92
Mexico, 19, 28, 53, 71–72, 93, 125, 135, 141, 172, 178, 186, 192, 231, 237, 257
Mongolia, 93
Morocco, 93
Myanmar, 93

N

Nepal, 14, 93–94, 141–142, 197–198 The Netherlands, 62, 65–66, 94, 125, 142, 178, 235 New Zealand, 72, 94, 113, 142, 158, 173, 178, 185 Nicaragua, 94 Niger, 155, 160 Nigeria, 62, 94, 160 Northern Ireland, 178 Norway, 94, 125, 192

P

Pakistan, 94, 135, 217
Panama, 94–95, 125–126, 178
Papua New Guinea, 95
Paraguay, 95
Peru, 45, 48, 95–96, 126
The Philippines, 96, 135
Poland, 72, 96, 126, 217–218
Portugal, 96, 162, 178
Puerto Rico, 19, 231

Index by Country/Area 275

R

Réunion Island, 96 Romania, 96 Russia, 20, 53, 69–70, 72, 97, 126, 142, 154–155, 186, 192, 218–219, 228–229, 236, 242, 257 Rwanda, 97

S

Saudi Arabia, 142 Scotland, 113 Senegal, 97–98, 126, 159 Sierra Leone, 98 Singapore, 98, 126–127 Slovakia, 72, 98, 192 Slovenia, 98, 127 South Africa, 19, 53–54, 70, 72, 98–99, 127, 142–143, 219, 229, 231 Spain, 54, 99–100, 113, 127, 192, 202–203 Sri Lanka, 100 Sudan, 100, 160 Suriname, 100 Sweden, 62–63, 100, 127, 158–159, 171, 173, 178, 185, 186, 199 Switzerland, 100, 112, 113, 171

T

Taiwan, 106, 112, 128, 164, 193
Tajikistan, 100
Tanzania, 100, 143
Thailand, 101, 133, 134, 143, 178, 185
Trinidad and Tobago, 101–102, 127–128
Tunisia, 102
Turkey, 102, 112, 128, 157, 175–176, 178, 235

U

Uganda, 102–104, 133, 134, 143, 219 Ukraine, 54, 104, 113, 126, 193 United Kingdom, 14–15, 31, 62, 66, 104–105, 128, 143–144, 171, 173, 178, 199, 200, 257 Uruguay, 61, 105

V

Venezuela, 105, 131–132, 178 Vietnam, 128, 133, 219

Υ

Yugoslavia, 105

7

Zambia, 105–106, 128, 144 Zimbabwe, 19–20, 106, 134, 155, 159, 231–232

276 Index by Country/Area

Index by Organization

Α

Actions for Building Capacity in Support of the International Collaboration in Infectious Disease Research Program, 48 Adult Psychological Development Branch, 61 Adult Psychopathology and Prevention Research Branch, 235-236 AIDS Clinical Trial Groups, 76–77 AIDS International Training and Research Program, 25, 26 AIDS-Fogarty International Research Collaboration Award, 41 American Dental Association, 156 Applications of Vision Research, 198 Applied Research Program, 129 Arthritis and Rheumatism Branch, 110, 111

В

Behavioral and Social Research Program, 61.64 Bioinformatics and Molecular Analysis Section, 259 Biological Psychiatry Branch, 240 Biological Testing Branch, 119 Biology of Aging Program, 61–62, 63 Biomaterials, Biomimetics, and Tissue Engineering Branch, 161 Biomedical and Behavioral Sciences Program, 54 Biomedical Imaging Program, 118 Biopysics Branch, 201 Biotechnology Engagement Program, 76, 97 Biotechnology Unit, 179 Bone and Connective Tissue Biology Branch, 110, 111-112

C

Cancer Therapy Evaluation Program, 118
Cell Biochemistry Section, 178
Cell Biology and Metabolism Branch, 145
Cell Biology Branch, 201
Cell Biology Section, 163
Cell Regulation Section, 175
Center for AIDS and STD Research, 80, 83, 89, 95, 96, 97, 102, 104
Center for AIDS Intervention Research, 232

Center for AIDS Prevention Studies, 232 Center for Clinical and Behavioral Studies, 232

Center for Early Detection, Prevention, and Treatment of HIV, 232

Center for Information Technology, 22, 259–260

Center for Mental Health Research on AIDS, 18–20, 230

Center for Scientific Review, 22–23, 261 Center for Vaccine Development, 81 Child Psychiatry Branch, 239 Chronic Diseases Branch, 160–161 Clinical and Cellular Biology Section, 174 Clinical and Endocrinology Branch, 173–174

Clinical Brain Disorders Branch, 240 Clinical Diabetes and Nutrition Section, 176 Clinical Endocrinology and Osteoporosis Research, 64

Clinical Neurogenetics Branch, 240
Clinical Neuropharmacology Section, 240
Clinical Neuroscience Branch, 239
Clinical Pathology Department, 263–264
Clinical Pharmacology Section, 243
Clinical, Behavioral, and Health
Promotion Research Branch, 161–162
Cognitive Neuroscience Section, 243
Collaborative Network for Clinical

Research on Immune Tolerance, 78 Comprehensive Research Center, 159 Computational Bioscience and Engineering Laboratory, 259 Consortium on Role of Stress in

Psychopathology, 237 Cooperative Group Program, 118

Craniofacial and Skeletal Diseases Branch, 154, 164–165

Craniofacial Anomalies and Injuries Branch, 157–158

Craniofacial Developmental Biology and Regeneration Branch, 163–164

Craniofacial Development Section, 111–112 Craniofacial Epidemiology and Genetics Branch, 164

Critical Care Medicine Department, 264

D

Demography and Population
Epidemiology Branch, 61
Department of Clinical Bioethics, 263
Department of Transfusion Medicine, 266
Developmental and Metabolic Neurology
Branch, 242–243
Developmental Biochemistry Section, 179
Developmental Endocrinology Branch, 145
Developmental Therapeutics Program,
118–119

Diabetes and Arthritis Epidemiology Section, 176

Diabetes Branch, 174

Diagnostic Radiology Department, 264 Division of AIDS, 76

Division of Cell Biology and Biophysics, 201 Division of Computational Biology, 259, 260 Division of Diabetes, Endocrinology, and Metabolic Disease, 169, 170–171

Division of Digestive Diseases and Nutrition, 170, 171–172, 173

Division of Epidemiology, Statistics, and Prevention Research, 134, 144–145

Division of Genetics and Developmental Biology, 201–202

Division of Intramural Research, 75 Division of Kidney, Urologic, and Hematologic Diseases, 172–173 Division of Microbiology and Infectious

Division of Microbiology and infectious

Diseases, 76

Division of Pharmacology, Physiology, and Biological Chemistry, 202

Division of Research Grants, 261 Division of Treatment, Research, and Development. 187

Drug Design and Synthesis Section, 179–180

Ε

Emerging Viral Diseases Research Centers, 76, 78, 83, 93, 105
Endocrinology and Reproduction Research Branch, 145–146
Enzyme Structure and Function Section, 176–177
Epidemiology and Demography Office, 63,

Index by Organization 277

Epidemiology, Demography, and Biometry Program, 59, 65–66 Epidemiology, Statistics, and Data System Branch, 151 European Organization for Research and Treatment of Cancer, 117, 129 European Union, 54, 155 Experimental Diabetes, Metabolism, and Nutrition Section, 174 Experimental Therapeutics Branch, 243

F

Fédération Dentaire Internationale, 155 Fogarty International Center, 156 Fogarty International Research Collaboration Award, 40–41

G

Gene Therapy and Therapeutics Branch, 165 Genetic Pharmacology Unit, 243 Genetics and Biochemistry Branch, 174 Genetics and Endocrinology Section, 175 Genetics of Development and Disease Branch, 174-175 Genetics of Simple Eukaryotes Section, 177 Genetics Projects, 236 Genetics Section, 111 Genetic Studies Section, 112 Geriatric Epidemiology Office, 63 Geriatric Psychiatry Branch, 240 Geriatrics Program, 62 Global Network for Women's and Children's Health Research, 132 Global Research Network on HIV Prevention in Drug-Using Populations, 188

н

Heritable Disorders Branch, 146
Hippocampal Interneuronal Network, 237
HIV Network, 76–80passim, 86–91passim, 97, 98, 101–106passim, 131
Hospital Epidemiology and Quality Assurance Service, 264
Human Cortical Physiology Section, 243
Human Frontier Science Program, 54–56
Human Genome Project, 17–18, 223

Image Processing Research Section, 259
Immunology Service, 263
Immunopathology Section, 167
Infectious Diseases and Immunity Branch, 158–160
Inflammatory Joint Diseases Section, 111
International Agency for Research on Cancer, 116, 123, 129

International AIDS Vaccine Master Contract, 76

International Association for Dental Research, 155–156

International Breast Cancer Screening Network, 129

International Centers for Tropical Disease Research Network, 76

International Collaboration in AIDS Research Program, 76

International Collaboration in Infectious Disease Research, 9, 76, 79–90*passim*, 95, 98–101*passim*, 107

International Cooperative Biodiversity Groups, 38–40, 118, 232–233

International Council on Alcohol and Addictions, 72

International Epidemiology Work Group on Drug Abuse, 188–189

International *Klebsiella* Study Group, 77 International League of Dermatological Societies. 109

International Maternal and Child Health Research and Training Program, 52

International Research Fellowship Program, 49, 51

International Research Scientist Development Award, 52

International Skeletal Dysplasia Registry, 133 International Training and Research in Environmental and Occupational Health Program, 194

International Training and Research Program in Emerging Infectious Diseases, 44–48

International Training and Research Program in Environmental and Occupational Health, 42–44

International Training and Research Program in Population and Health, 44, 45

International Training in Medical Informatics Program, 52

International Union Against Cancer, 116, 129

Intramural Research Laboratory Program, 66–67

J

John E. Fogarty International Center for Advanced Study in the Health Sciences, 3–5, 35–57

Joint Project on Disablement, 72

K

Kidney Diseases Section, 175

L

Laboratories of the Scientific Director, 150
Laboratory of Adaptive Systems, 244
Laboratory of Biochemistry and Genetics, 176–177, 214–215, 216
Laboratory of Biological Chemistry, 66
Laboratory of Bioorganic Chemistry, 13–14, 177–178
Laboratory of Brain and Cognition, 239
Laboratory of Cardiovascular Science, 66
Laboratory of Cell Biochemistry and

Biology, 177–179 Laboratory of Cell Biology, 240 Laboratory of Cell Signaling, 217 Laboratory of Cellular and Developmental Biology, 179

Laboratory of Cellular and Molecular Biology, 66

Laboratory of Cellular and Molecular Biophysics, 146–147

Laboratory of Cellular and Molecular Neurophysiology, 147

Laboratory of Cellular Biology, 151 Laboratory of Cellular Molecular Regulation, 240

Laboratory of Central Nervous System Studies, 244

Laboratory of Cerebral Metabolism, 240 Laboratory of Chemical Physics, 179 Laboratory of Clinical Investigation, 66–67, 80

Laboratory of Clinical Science, 240 Laboratory of Clinical Studies, 73 Laboratory of Comparative Ethology, 147 Laboratory of Developmental and Molecular Immunity, 147–148 Laboratory of Developmental

Neurobiology, 148 Laboratory of Diagnostic Radiology

Research, 264 Laboratory of Eukaryotic Gene Regulation,

148 Laboratory of Genetics, 64–65, 67, 73, 240

Laboratory of Genomic Diversity, 128 Laboratory of Immunology, 67 Laboratory of Immunoregulation, 7, 9, 77,

Laboratory of Infectious Diseases, 81, 99 Laboratory of Integrative and Medical Biophysics, 148

Laboratory of Malaria Research, 76 Laboratory of Mammalian Genes and Development, 148–149

Laboratory of Mechanisms of Ocular Disease, 199

Laboratory of Medicinal Chemistry, 179–180

278 Index by Organization

Laboratory of Membrane Biochemistry and Biophysics, 73 Laboratory of Microbial Structure and Function, 81 Laboratory of Molecular and Cellular

Biology, 180-181

Laboratory of Molecular and Cellular Neurobiology, 73

Laboratory of Molecular and Developmental Biology, 198

Laboratory of Molecular Biology, 180, 240, 244

Laboratory of Molecular Endocrinology, 149 Laboratory of Molecular Genetics, 67, 149, 151

Laboratory of Molecular Growth Regulation, 149

Laboratory of Molecular Medicine and Neuroscience, 244–245

Laboratory of Neural Control, 245

Laboratory of Neurochemistry, 240 Laboratory of Neurophysiology, 245

Laboratory of Neuropsychology, 240 Laboratory of Parasitic Diseases, 76, 80, 82,

Laboratory of Personality and Cognition, 67 Laboratory of Physical and Structural Biology, 149-150

Laboratory of Physical Biology, 110, 112 Laboratory of Sensorimotor Research, 199 Laboratory of Skin Biology, 110, 112–113 Laboratory of Socio-Environmental Studies, 240

Laboratory of Structural Biology Research, 110. 113

Laboratory of Systems Neuroscience, 240 Laryngeal and Speech Section, 243 Liaison Office, 117-118 Lipid Cell Biology Section, 178–179 Lymphocyte Cell Biology Section, 111

Macromolecular Biophysics Section, 112 Malaria Program Project, 80 Mammalian Developmental Biology Section, 179 Maternal-Fetal Medicine Units Network, 132 Mathematical and Statistical Computing Laboratory, 260 Mathematical Research Branch, 175 Matrix Metalloproteinase Unit, 154, 167 Medical Neurology Branch, 243 Membrane Biology Section, 165 Membrane Regulation Section, 179 Metabolic Diseases Branch, 175 Microbiology Service, 263-264

Index by Organization

Middle East Cancer Consortium, 12 Middle East Hypertension Initiative, 209 Middle Eastern Regional Contract, 89, 91,

Minority International Research Training Program, 50, 51

Molecular and Cellular Neuroscience Research Branch, 236

Molecular and Cellular Physiology Section,

Molecular and Clinical Hematology Branch, 176

Molecular Biology and Gene Regulation Section, 174

Molecular Biology of Keratinization Section, 112-113

Molecular Biology Section, 180

Molecular Mechanisms of Development Section, 179

Molecular Medicine and Virology Section,

Molecular Pathophysiology Section, 175-176

Molecular Regulation and Neuroendocrinology Section, 174 Molecular Structural Biology Unit, 168 Morphogenesis Section, 177 Multilateral Initiative on Malaria, 54 Muscle Biophysics Section, 112 Mycoses Study Group, 77, 80

National Cancer Institute, 11-12, 115-129 National Center for Complementary and Alternative Medicine, 22, 253-254 National Center for Research Resources. 22, 255-257

National Center on Sleep Disorders Research, 221

National Eye Institute, 14–15, 197–200 National Heart, Lung, and Blood Institute, 16-17, 205-221

National Human Genome Research Institute, 17-18, 223-226

National Institute of Allergy and Infectious Diseases, 7, 9, 75-107

National Institute of Arthritis and Musculoskeletal and Skin Diseases, 9-11, 109-113

National Institute of Child Health and Human Development, 12-13, 131-150

National Institute of Dental and Craniofacial Research, 13, 153–168

National Institute of Diabetes and Digestive and Kidney Diseases, 13-14, 169-181

National Institute of Environmental Health Sciences, 15–16, 191–195 National Institute of General Medical Sciences, 16, 201-203

National Institute of Mental Health, 18–20, 227–240

National Institute of Neurological Disorders and Stroke, 20-21, 60, 241-245

National Institute of Nursing Research, 21-22, 247-248

National Institute on Aging, 5, 7, 59–67 National Institute on Alcohol Abuse and Alcoholism, 7, 69–73

National Institute on Deafness and Other Communication Disorders, 13, 151–152 National Institute on Drug Abuse, 15,

183-189

National Library of Medicine, 22, 249-253 Natural Products Branch, 119 Neoplastic Diseases Branch, 160 Neuroepidemiology Branch, 243-244 Neuroepidemiology Office, 60, 63-64 Neuroinformatics Program, 233 Neuropharmacology Program, 236 Neurophysiological Pharmacology Section,

Neuroscience and Neuropsychology of Aging Program, 62–63 NIH Visiting Program, 56 Nuclear Medicine Department, 264–265 Nucleic Acids Biochemistry Section, 180 Nursing Department, 265

Office of AIDS Research, 25-27 Office of Behavioral and Social Sciences Research, 31–32 Office of Demography of Aging, 5 Office of Dietary Supplements, 29–30, 133 Office of Disease Prevention, 29–31 Office of Education, 33 Office of Extramural Research, 32 Office of Human Subjects Research, 33 Office of International and Refugee Health, 60 Office of International Health, 13, 153 Office of Intramural Research, 32–33 Office of Neuroinformatics, 233 Office of Nutrition, 64 Office of Protection From Research Risks, 32 Office of Rare Diseases, 30-31 Office of Research on Minority Health,

28-29

Office of Research on Women's Health, 27 - 28Office of the Director, 25-33

279

Office on Neuroinformatics, 238
Oral and Pharyngeal Cancer Branch,
166–167

Oral Infection and Immunity Branch, 165–166

Organization for Economic Cooperation and Development, 233

Organization of European Cancer Institutes, 129

P

Pacific Institute for Research and Evaluation, 71
Pain and Neurosensory Mechanisms
Branch, 167
Pan American Health Organization, 89, 107, 129, 208
Perinatology Research Branch, 146
Pharmacy Department, 265–266
Phoenix Epidemiology and Clinical Research Branch, 169–170, 176
Physical Biochemistry Section, 177
Positron Emission Tomography Department, 266
Preparing for AIDS/HIV Vaccine

Proton Radiation Oncology Group, 128-129

Evaluation, 76

R

Receptors and Hormone Action Section, 174 Rehabilitation Medicine Department, 266 Reproductive Sciences of the Americas Network, 133 Research Institute of Tropical Medicine, 77

Research Resources Branch, 67

S

Scholars-in-Residence Program, 48–49 Scientist Exchange Programs, 115–116 Secretory Physiology Section, 165 Section on Carbohydrates, 179 Section on Clinical and Experimental Neuropsychology, 239 Section on Genomic Structure and Function, 180 Section on Pharmacology, 240 Senior International Fellowship Program, 49 Signal Transduction Group, 111 Skin Diseases Branch, 109–110 Steroid Hormones Section, 180–171 Steroid–Catecholamine Interactions and Behavior, 237-238 Stroke Branch, 244

Т

Trauma Studies, 236–237
Tropical Disease Research Unit, 76, 102, 104
Tropical Medicine and International
Research, 76
Tropical Medicine Research Center, 9, 76, 82, 83, 92, 96
Tuberculosis International Training and
Research Program, 37–38
Tuberculosis Research Center, 76
Tuberculosis Research Unit, 87, 90, 103–104

U

United Nations, 134
Unit on Neurobiology, 240
U.S. Civilian Research and Development
Foundation, 54
U.S.-European Commission, 234

V

Viral Hepatitis Research Centers, 76

W

Warren Grant Magnuson Clinical Center, 23, 263–266 World Health Organization, 72, 107, 134, 155, 169–170, 187–188, 229, 230, 253–254

280 Index by Organization

_		
A	anthrax toxin, 166	bilirubin, 146
abacavir, 94	antihelminthic drugs, 103	binge drinking, 71
abortion, 135	antiretroviral drugs, 79, 81	biochemistry, 174, 176–177, 180, 187, 214
acetylcholine, 55	apartheid, 229	biodiversity, 38–40, 94, 100, 118, 232–233
achondroplasia, 175	apolipoprotein A-1, 210	bioengineering, 201
acid maltase deficiency, 30	Arabidopsis, 55–56	bioethics, 263
acromegaly, 171	Arctic, 32–33	biofilms, oral, 158
actin-myosin bonding, 175	arsenic, 192	bioinformatics, 258–260
acyl coenzyme A, 171	arteriosclerosis, 216	see also genomes
adaptive systems, 244	artesunate, 92	biokinetics, lead, 16
addictions. See alcohol abuse and alcoholism	arthritis, 9–11, 109–113	biological chemistry, 66, 202
adenosine, 178, 212–213	asbestos, 127	biological psychiatry, 240
adolescents, 15, 184, 227	Ascaris infection, 94	biological testing, cancer therapy, 119
see also children	ascites, 172	biomarkers, 124, 194, 256
Aedes aegypti, 93, 102	asthma, 17, 96, 100, 208–214passim,	cancer, 120, 122
aflatoxin, 193	218, 220	biomaterials, 161
African Americans, diabetes mellitus,	astrovirus, 93	biomedical sciences, 54
224–225	ataxia-telangiectasia, 83, 123, 124	biometry, aging, 59
aging, 5, 7, 27–28, 59–67, 156, 161, 199, 240	atherosclerosis, 216	biomimetics, 161
AIDS. See HIV/AIDS	attachment patterns, 144	biomineralization, 158
air pollution, 192, 193	audiovisual materials, cancer, 117	bioorganic chemistry, 177–178
airways, remodeling of, 212	autism, 140	biophysics, 112, 146–147, 148, 201
albendazole, 94	autoimmune disease, 89, 175	biotechnology, 56, 97, 179, 202, 234
alcohol abuse and alcoholism, 7, 69–73	autonomic nervous system, alcohol and, 71	bipolar disorder, 236
prevention, 69–70	azithromycin, 77, 85, 103	black fly, 109–110
algorithms, 257	AZT. See zidovudine	blacks, 219
alkaloids, 13, 177, 178		bladder cancer, 127
allergens, 98	В	blinding diseases, 200
allergy, 75–107	bacille Calmette-Guérin vaccine, 83	Blomia tropicalis, 98
allograft pathology, 173	Bacillus subtilis bacteriophage, 16, 202–203	blood diseases, 16–17, 205–221
alternative medicine, 22, 253–254	bacteria, 49, 162	B lymphocytes, 78
Alzheimer's disease, 65, 240, 243	bacterial complexes, 158–159	boating injuries, alcohol and, 72
AmBisome, 89	bacterial diseases, 9, 77–107 passim	bombing, 228
amebiasis, 85	bacteriophage, 202–203	bone, 110, 111–112
amebic abscesses, 85, 98, 99	balance, 60	animal model, 13
amoxicillin–clavulanate, 102	Bartonella spp., 96	mineral, 136
amphotericin B, 87, 89	Batten disease, 31	protein, 112, 165
amputees, 243	Bcl, 160	bone marrow transplantation, 128, 219
amygdala, 65	behavior, 72, 136, 137, 143, 184, 227,	Bordetella pertussis, 81, 83, 98, 100
amyotrophic lateral sclerosis, 243	237, 243	botulinum toxins, 148
Anatomical Digital Database, 251	HIV/AIDS, 82, 89, 231–232	bowel disorders, 172
Ancyclostoma caninum, 82	behavioral interventions, community-	brain, 54-55, 62-63, 67, 123, 136, 183,
anemia, 90, 136	based, 37	227, 236, 240
angiogenesis, 163	behavioral research, 31–32, 61	development, 137, 180, 235
animal models, 20-21, 83, 88-89, 128,	behavioral sciences, 54	BRCA1/2, 124
154, 164, 167, 175, 198, 218, 241	benzene, 122	breast
Anopheles spp., 84, 92, 96, 98, 102	biliary tract cancer, 122	cancer, 119-120, 124-129 passim, 225

milk, 193	β-carotene, 123	clinical biology, 174
self-examination, 122	cartilage, aging, 62	clinical investigations, 23, 66–67, 73,
breast-feeding, 131, 141	cat, 128	169–170, 263–266
B5R protein, 100	cataract, 197, 198–199, 200	clinical pathology, 263–264
BufferGel, 101	cefiximine, 103	clinical science, 240
buprenorhine, 187	cell biology, 66, 123, 145, 173–181 <i>passim</i> ,	clinical trials, 7, 81– 86 <i>passim</i> , 103, 117,
bypass angioplasty revascularization, 212	198, 201, 217, 240	118, 125, 128, 132, 212
G I way	neuroscience, 147, 236	cocaine, 186
С	see also membrane	cognition, 61, 67, 239
caffeine, 178	cell lines	cognitive development, 137, 147
calcium, 15, 165, 200	mutant cell repository, 203	cognitive neuroscience, 243
channel, 5, 7	neuronal, 214	collagen-related peptide, 49
Callitrichid spp., 256	cellular neurobiology, 73	colorectal cancer, 121, 126
canarypox, 79, 86, 101	central nervous system, 71, 151, 177, 178,	commercial sex workers, 89
cancer, 116–129, 163, 248	244	communication disorders, 13, 151–152
biliary tract, 122	cephalic phase response, 30	complementary medicine, 253–254
biomarkers, 120, 122	cephalosporins, 99	Composite International Diagnostic Interview,
bladder, 127	cerebral metabolism, 240	228
brain, 123	cerebral palsy, 136	condom promotion, 97
breast, 119-120, 124-129 passim, 225	cervical cancer, 12, 96, 97, 103, 120, 127	conexin genes, 123
care, 118, 265	cervical dysplasia, 142	congenital eye infection, 197
colorectal, 121, 126	cesarean delivery, 21, 135, 247	connective tissue biology, 110, 111–112
diagnostics, 121, 129	CFTR protein, 170	contraception, 103, 127, 132–133, 134,
endometrial, 127	Chagas' disease, 77, 79, 86	138, 144
esophageal, 126	chemical physics, 179	COPD. See pulmonary disease
genetics, 128, 166–167, 225	chemistry, 179–180	coronary heart disease, 205–206
head and neck, 166	chemokine receptors, 88, 100	corticotropin-releasing hormone, 180
incidence, 122, 192	chemokines, 212	craniofacial anomalies and injuries,
information, 116-117, 129, 258-260	chemotherapy, 127	157–158
liver, 122, 126	Chernobyl, 126	craniofacial development, 111–112, 163
lung, 122, 123, 124	children, 12–13, 71, 83–88passim, 94,	craniofacial health and disease, 13, 159,
nasopharyngeal, 126–127	131–150, 151, 162, 170, 172, 176, 183,	164–165
occupational risks and, 123, 124, 126,	216, 219, 231–232, 239, 243–244, 256	see also oral health
127, 128	asthma, 212, 214	critical care medicine, 264
oral and pharyngeal, 126–127, 160,	bacterial disease, 79, 96	Crohn's disease, 30
166–167	HIV, 37, 91, 94	Cryptococcus spp., 88
ovarian, 128	malaria, 85, 90	Cryptosporidium spp., 87, 88, 94, 95
prostate, 123, 124, 127, 134, 225	mental health, 227, 239	crystallographic data, 22
registries, 116,124, 127, 128	mortality, 26, 100	CTNS gene, 146
renal, 12, 120	vision, 197–198	Culex pipiens, 93
statistics, 12, 121, 129	see also HIV transmission, mother-to-child	culture, 184
stomach, 126	chimpanzees, 91, 98, 99	pain and, 161–162
testicular, 128	Chlamydia pneumoniae, 218	curdian sulfate, 106
thyroid, 48–49, 126, 128	Chlamydia trachomatis, 86, 89, 93, 102	cystic fibrosis, genes, 170
CancerMail, 116–117	chloroquine, 92	cysticercosis, 3, 44–45, 48, 95
Candida, 88, 104, 256	cholera, 78, 87, 95	cytokines, 111, 244
cannabis, 15, 186	cholera toxin, 89, 106	cytomegalovirus, 84, 86, 94, 106
prenatal exposure, 183	cholesterol, 210	
capacity-building, 48	chromosomal 12q markers, 78	D
carageenan-based microbicide, 99	chromosome 22, 18, 223–226	databases, 30, 224, 258
carbohydrates, 179	chronic diseases, 160–161, 228	anatomical, 251
carcinogenicity, 14, 122, 123	chymotrypsin, 149	microbes, 257
carcinogens, 129, 178	ciprofloxacin, 100, 103	migration, 135
cardiopulmonary disease, 206–207, 210, 217	circadian rhythm, 54	neuroscience, 233–234
cardiovascular disease, 31, 59–60, 66, 177,	cirrhosis, 215	protein, 203
209, 212–220passim	cleft lip and cleft palate, 157–158	DDT, 125

deafness, 13, 151–152	abuse, 15, 183–189	expenditures, total, 4–5
deconvolution, 257	dependence, perinatal, 28	eye, 197–200
Deet, 89	development, 117, 179–180	eye bank, 198
delavirdine, 99	discovery, 119, 187, 233	see also vision
dementia, 60, 62, 178	resistance, 87, 92, 93, 99, 100	
demography, 59, 61, 132	trafficking, 37, 70	F
dengue fever, 93, 100, 101	users, 187, 188	factory workers, HIV, 106
dengue virus, 79, 94, 105	d4T, 99	familial Mediteranean fever, 111
dental amalgam, 162	dust mite, immunology, 86	family, 136–137
dental caries, 158		family planning, 134, 135, 138
dental research, 13	E	Fasciola spp., 84
dental treatments, utility, 161	eating, 30	fatty acids, 30
depot medroxyprogesterone acetate, 127	echinococcosis, 90, 95	fenretinide, 124
depression, 228	E. coli. See Escherichia	fetal alcohol syndrome, 7, 70, 72, 145
dermatitis, 102	economics, 138-139, 141-142	fetal infections, 90
developing countries	see also socioeconomics	fetal origins of adult disease, 28
biodiversity, 40	education, 33	FGFR2 gene, 112
cancer registries, 116	ehrlichiosis infection, 80	fibroblasts, 213
scientific activity, 187	electronic information, cancer, 116–117	filariasis, 83, 86, 87, 90
development	see also MEDLINE	bancroftian, 83, 84, 95
biology, 163–164, 179, 198, 201–202	embryo culture, bovine, 136	fish malodor syndrome, 31
biochemistry, 179	embryology, molecular, 149	fleas, 100
disabilities, 256	emerging diseases, 2	fluoride use, 154
molecular mechanisms, 179	enteric, 95	5-fluorouracil, 126
neurology, 242–243	infectious, 44–48, 56, 159–160	fragile X syndrome, 149
therapeutics, 118–119	see also infectious diseases	funding mechanisms, 3
dexamethasone, 192	emerging technologies, 1	
diabetes mellitus, 13–14, 66–67, 89,	emtricitabine, 83	G
169–181, 199, 224–225	enamel formation, 158	G7 Global Healthcare Applications project,
diarrhea, 79, 81, 87–88, 95, 141	encephalitis, equine, 83, 93, 105	251
chronic, 79, 88, 105	encephalomyelitis, 96, 242	Gaucher disease, 239
dichloroacetate, 85	endocrinology, 145–146, 169, 173–174,	gender, immune competence and tumor
dideoxynucleoside, 99	175, 180	development, 124
diet, 120–121, 122–123, 126, 136, 138,	endometrial cancer, 127	general medical sciences, 201–203
172, 177, 216	Entamoeba histolytica, 78, 85, 93, 98, 99	genes and genetics, 30, 31, 55–56, 67, 73,
dietary supplements, 29–30, 133, 139, 173	enteric diseases, 26, 78, 98	82–88passim, 92, 111, 126,
digestive diseases, 13–14, 171–172, 173	envelope protein, 81	145–149 passim, 160, 164, 166, 170,
dihydrofolate reductase, 84	environment, 15-16, 138-139	174-177 passim, 184, 192, 193, 201-202,
dioxin, 124, 193	Arctic, 32–33	206, 214, 227, 236, 239, 240, 258, 264
diphtheria–pertussis–tetanus, 85	environmental health sciences, 42-44, 56,	addiction, 185, 186
disabilities, assessment, 230	191–195	aging, 65, 66, 67
disablement, alcohol-induced, 72	enzymes, 149, 176–177	behavior, 140, 144
disaster recovery, 237	epidemiology, 143, 144–145, 164, 176,	cancer, 128, 160, 166–167
disease prevention, 29–31	197, 213, 264	craniofacial development, 112, 157-158,
DNA, 149, 150, 167, 198	aging, 59–66passim	164
polymorphism, 18, 224	drug abuse, 188–189	development, 148-149, 174-175
DNA–protein complex, 202–203	HIV, 86, 159	diabetes, 171, 176
DOCLINE, 249, 250–251	epidermal growth factor, 111, 112	endocrinology, 174, 177, 216
document delivery, 249	epitope mapping, 83	mapping, 2, 172–173, 203
dogs, 102	Escherichia coli, 87, 88, 93, 145	microbial, 79, 80, 82
dopamine, 184, 186	esophageal cancer, 126	molecular, 149, 151
Down syndrome, 137	esophageal varices, 172	regulation, 148, 174
driving, alcohol and, 71	estrogen, 164, 212	skin, 109, 112
Drosophila, 55, 106, 135	ethology, 147	taste receptors, 13, 154
drowning, alcohol and, 72	eukaryotes, genetics, 148, 177	therapy, 146, 165
drugs	exercise, 172	vision, 198, 199

genital ulcer diseases, 87, 100 genomes, 17–18, 67, 112, 128, 135, 143,	HHV-8. <i>See</i> human herpesvirus 8 Hib, 85	ilariasis, 90 imaging, 118
164, 167, 180, 213–214, 224	hippocampal interneuronal network, 237	immunization. See vaccines
human, 223–226	hippocampus, 65 Hiroshima, 126	immunoglobulins, 80, 164
geriatrics. See aging	histocompatibility, 90–91, 147	immunology, 7, 9, 67, 110, 123, 147–148,
Giardia, 87, 88, 104		158–160, 165–166, 263
gingival fibromatosis, 160	HIV/AIDS, 3–4, 7, 9, 12, 25–27, 37, 41, 76–105passim, 125–128passim, 144, 158,	genes, 31, 257
gingival fibromatosis, 160 gingivitis, 160, 164	173, 178, 185–186, 212, 219, 231, 240,	infectious diseases, 9, 77, 78, 83, 86, 90–91, 94–98 <i>passim</i> , 102, 106
girls, education, 140	244–245, 257, 260	immunosuppression, 100
GIV-1, 100	clades and subtypes, 86, 94, 98,	infants, 80, 81, 82, 95, 159, 172, 248
glaucoma, 142, 199	102–106 <i>passim</i>	see also children; HIV transmission,
glioblastoma, 214	discordant couples, 83, 86, 103	mother-to-child
glucocorticoid production, 106	genetics, 89, 96	infant mortality, 143
glutaric acidemia, 136	mental health, 18–20, 230	infectious disease, 30, 47, 75–107, 140,
glycation, 217	prevention, 18-20, 25–26, 86–87, 101,	158–160
glycoproteins, 202	188, 230–231, 232	see also emerging infectious diseases
glycosphingolipids, 175	training and research, 35–37	inflammation, 9–10, 166, 264
Golden Triangle, 37		influenza, 82, 89, 97, 104–105
gonadotropin-releasing hormone, 256	treatment, 7, 49, 80, 102, 231, 232 see also vaccines	informatics, training, 51, 52
gonorrhea, 89	HIV transmission, 36–37	information technology, 22, 258–260
gp20, 86	heterosexual, 83, 89–90, 94, 101	inherited diseases, tracing, 18
gp120, 79, 101, 143	intravenous drug use, 106	injuries, 69, 134, 157–158
G protein, 166, 178	mother-to-child, 36–37, 57, 84–91	inositol, 131
G protein-coupled receptors, 183–184	passim, 98, 102–106passim, 123, 131,	insulin, 131–132
graft rejection, 89	132, 140, 142–143, 166	insulin-like growth factor, 122, 124
gramicidin A, 150	sexual, 37, 101, 102, 106, 133, 143, 144,	insulin-secreting cells, 170
grants, 261	159, 186	integrative biophysics, 148
growth and development, 91, 138	hookworm, 77, 82	integrative biophysics, 148
growth factors, 111–112	hormone replacement therapy, 212	interleukin, 87, 88
growth regulation, molecular, 149	hormones, 145–146, 171, 174, 180–181	IL-2, 99, 123
giowth regulation, molecular, 149	hospital-acquired infections, 94, 99	IL-4, 80
н	hospital restructuring, 21	IL-8, 215
HAART. See HIV/AIDS, treatment	household size and composition, 136	IL-10, 102
Haemophilus ducreyi, 94, 101	Hoxb gene, 144	international agreements, 1999, 2
Haemophilus influenzae, 82, 89, 104, 142	H. pylori. See Helicobacter	International Classification of Diseases, 134,
Hantaviruses, 81–82, 95	HTLV-1/2, 87, 89, 124–125, 125–126, 127	142
head and neck cancer, 166	Human Genetic Mutant Cell Repository, 203	International Classification of Impairments,
health behavior, 134	human herpesvirus 8, 89, 92, 106, 123,	Disabilities, and Handicaps, revision, 20,
health insurance, 137	125, 128, 159	229–230
hearing loss, 151	human papillomavirus, 88, 93, 121,	international research and research
heart disease, 16–17, 65, 205–221	126, 127	training awards, 8–11
Helicobacter pylori, 82, 95, 97, 125	human subjects, 32, 33	international scientific activities
helminth infections, 77, 90	hydatidosis, 90	(overview), 3–23
hematologic diseases, 173	hyperbilirubinemia, 135, 138	funding by mechanism, 3
hematology, 176	hyperkinesia in schizophrenia, 255	Internet, 250, 251
hepatic encephalopathy, 178	hyperparathyroidism–jaw tumor	intravenous drug users, 106
hepatitis, 97, 101, 219	syndrome, 175	iron, 137, 173
A, 172	hypersensitivity, 102	Ixodes spp., 85
B, 81, 85, 101, 122, 126	hypertension, 16–17, 21, 199, 207–208,	mones spp., ee
C, 82, 99, 101, 125, 165–166, 172, 173,	209, 213–220 <i>passim</i> , 241–242, 255	J
247–248	hypomyelination, 136	joint diseases, inflammatory, 111
hepatocellular carcinoma. <i>See</i> liver cancer) r ,	,
heritable disorders, 146, 224	1	К
heroin, 186	IFN-α, 80, 95, 102	kala-azar, 80, 87
herpes simplex, 101, 256	IL. See interleukin	Kaposi's sarcoma, 106, 128

Kenny-Caffey syndrome, 140	see also nutrition	molecular regulation, 174
keratinization, 112–113	mammalian developmental biology, 179	molecular structures, 239
kidney, 178	manganese superoxide dismutase gene, 217	morbidity, 60, 132
kidney disease, 13-14, 169-181, 173, 175	mannosidase, 16, 202	morphogenesis, 177
Klebsiella, 9, 77	MAP kinases, 167	mortality, 28, 60, 132, 137
KM-3 protein, 83	marijuana. See cannabis	infants and children, 26, 143
	marmosets, 256	mosquitoes, 93
L	marriage, 135	motor development, 137
lactoferrin, 142	maternal and child health, 4–5, 52	M2 protein, 89
lamivudine, 98, 99	mathematics, 175	MRI scans, 239
language development, 132, 137, 147	matrix metalloproeinase, 154, 167	Muriqui monkeys, 256
larynx, 243	medicinal chemistry, 179–180	muscle biophysics, 112
laser technology, 179	MEDLARS, 249	musculoskeletal diseases, 9–11, 109–113
Lassa fever virus, 98	MEDLINE, 116–117	mutagenesis, 144
lead, 193	melanoma, 123, 124, 125	mutagenicity, 123
pregnancy and, 16, 191	melatonin, 256	mutations, 10, 109, 147, 192
Leishmania chagasi, 82–89passim, 102, 172	membrane, 73, 165, 179	Mycobacterium
leishmaniasis, 79–80, 90, 91, 93, 100, 102	memory, 55	avium, 78, 96
lens development, 200	meningococcus, 77	avium-intracellulare, 83
leprosy, 80, 84, 96	menopause, 64, 124, 215–216	leprae, 80
leukemia, 124, 128	mental health, 27, 144, 227–240	tuberculosis, 78, 80, 84, 87, 88,
leukotriene C4, 96	AIDS, 18–20	93–96 <i>passim</i> , 99, 103, 104
library, 22, 249–251	mental illnesses, severe, 229	mycotic diseases, 77, 80, 88, 89, 96, 104
lifestyle, 134	mercury, 194	myf5, 137
ligands, 180	metabolic diseases, 169, 175–176	myocardial infarction, 213
lipid cell biology, 178–179	metabolic neurology, 242–243	myocardial troponin 1 variants, 212
lipopolysaccharide, 98 liver	metabolism, 73, 145, 171, 174	myometrium, 136
livei	metastases, 163	
cancer 122 126		N
cancer, 122, 126	methamphetamine, 15, 183	N Nagasaki 126
damage, alcohol induced, 70-71	methamphetamine, 15, 183 metronidazole, 103	Nagasaki, 126
damage, alcohol induced, 70–71 disease, 173, 215	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133	Nagasaki, 126 naltrexone, 186
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71 lower-leg ulcers, chronic, 109	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264 micronutrients, 30, 37, 78, 98, 133, 139, 154	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127 nasopharyngeal implantation of radium,
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71 lower-leg ulcers, chronic, 109 lung	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264 micronutrients, 30, 37, 78, 98, 133, 139, 154 Middle East Hypertension Initiative, 209	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127 nasopharyngeal implantation of radium, 125
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71 lower-leg ulcers, chronic, 109 lung cancer, 122, 123, 124	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264 micronutrients, 30, 37, 78, 98, 133, 139, 154 Middle East Hypertension Initiative, 209 migration, 135, 136–137, 140–141, 235,	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127 nasopharyngeal implantation of radium, 125 natural products, cancer therapy, 119
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71 lower-leg ulcers, chronic, 109 lung cancer, 122, 123, 124 disease, 16–17, 193, 212	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264 micronutrients, 30, 37, 78, 98, 133, 139, 154 Middle East Hypertension Initiative, 209 migration, 135, 136–137, 140–141, 235, 236–237, 240	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127 nasopharyngeal implantation of radium, 125 natural products, cancer therapy, 119 needle-stick injuries, 44
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71 lower-leg ulcers, chronic, 109 lung cancer, 122, 123, 124 disease, 16–17, 193, 212 morphogenesis, injury, and repair, 212	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264 micronutrients, 30, 37, 78, 98, 133, 139, 154 Middle East Hypertension Initiative, 209 migration, 135, 136–137, 140–141, 235, 236–237, 240 miltefosine, 87	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127 nasopharyngeal implantation of radium, 125 natural products, cancer therapy, 119 needle-stick injuries, 44 Nef protein, 98
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71 lower-leg ulcers, chronic, 109 lung cancer, 122, 123, 124 disease, 16–17, 193, 212 morphogenesis, injury, and repair, 212 Lutzomyia, 80, 105	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264 micronutrients, 30, 37, 78, 98, 133, 139, 154 Middle East Hypertension Initiative, 209 migration, 135, 136–137, 140–141, 235, 236–237, 240 miltefosine, 87 minorities	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127 nasopharyngeal implantation of radium, 125 natural products, cancer therapy, 119 needle-stick injuries, 44 Nef protein, 98 Neisseria gonorrhoeae, 102, 105, 106
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71 lower-leg ulcers, chronic, 109 lung cancer, 122, 123, 124 disease, 16–17, 193, 212 morphogenesis, injury, and repair, 212 Lutzomyia, 80, 105 Lyme disease, 85, 100	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264 micronutrients, 30, 37, 78, 98, 133, 139, 154 Middle East Hypertension Initiative, 209 migration, 135, 136–137, 140–141, 235, 236–237, 240 miltefosine, 87 minorities health, 28–29	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127 nasopharyngeal implantation of radium, 125 natural products, cancer therapy, 119 needle-stick injuries, 44 Nef protein, 98 Neisseria gonorrhoeae, 102, 105, 106 nelfinavir, 81, 99
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71 lower-leg ulcers, chronic, 109 lung cancer, 122, 123, 124 disease, 16–17, 193, 212 morphogenesis, injury, and repair, 212 Lutzomyia, 80, 105 Lyme disease, 85, 100 lymphocyte cell biology, 111	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264 micronutrients, 30, 37, 78, 98, 133, 139, 154 Middle East Hypertension Initiative, 209 migration, 135, 136–137, 140–141, 235, 236–237, 240 miltefosine, 87 minorities health, 28–29 training grants, 50–51	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127 nasopharyngeal implantation of radium, 125 natural products, cancer therapy, 119 needle-stick injuries, 44 Nef protein, 98 Neisseria gonorrhoeae, 102, 105, 106
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71 lower-leg ulcers, chronic, 109 lung cancer, 122, 123, 124 disease, 16–17, 193, 212 morphogenesis, injury, and repair, 212 Lutzomyia, 80, 105 Lyme disease, 85, 100	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264 micronutrients, 30, 37, 78, 98, 133, 139, 154 Middle East Hypertension Initiative, 209 migration, 135, 136–137, 140–141, 235, 236–237, 240 miltefosine, 87 minorities health, 28–29 training grants, 50–51 mite allergens, 77	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127 nasopharyngeal implantation of radium, 125 natural products, cancer therapy, 119 needle-stick injuries, 44 Nef protein, 98 Neisseria gonorrhoeae, 102, 105, 106 nelfinavir, 81, 99 nephropathy, 173
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71 lower-leg ulcers, chronic, 109 lung cancer, 122, 123, 124 disease, 16–17, 193, 212 morphogenesis, injury, and repair, 212 Lutzomyia, 80, 105 Lyme disease, 85, 100 lymphocyte cell biology, 111	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264 micronutrients, 30, 37, 78, 98, 133, 139, 154 Middle East Hypertension Initiative, 209 migration, 135, 136–137, 140–141, 235, 236–237, 240 miltefosine, 87 minorities health, 28–29 training grants, 50–51	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127 nasopharyngeal implantation of radium, 125 natural products, cancer therapy, 119 needle-stick injuries, 44 Nef protein, 98 Neisseria gonorrhoeae, 102, 105, 106 nelfinavir, 81, 99 nephropathy, 173 nerve fibers, severed, 241
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71 lower-leg ulcers, chronic, 109 lung cancer, 122, 123, 124 disease, 16–17, 193, 212 morphogenesis, injury, and repair, 212 Lutzomyia, 80, 105 Lyme disease, 85, 100 lymphocyte cell biology, 111 lymphoma, 124	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264 micronutrients, 30, 37, 78, 98, 133, 139, 154 Middle East Hypertension Initiative, 209 migration, 135, 136–137, 140–141, 235, 236–237, 240 miltefosine, 87 minorities health, 28–29 training grants, 50–51 mite allergens, 77 molecular regulation, 240	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127 nasopharyngeal implantation of radium, 125 natural products, cancer therapy, 119 needle-stick injuries, 44 Nef protein, 98 Neisseria gonorrhoeae, 102, 105, 106 nelfinavir, 81, 99 nephropathy, 173 nerve fibers, severed, 241 nerve growth factor, 112, 150
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71 lower-leg ulcers, chronic, 109 lung cancer, 122, 123, 124 disease, 16–17, 193, 212 morphogenesis, injury, and repair, 212 Lutzomyia, 80, 105 Lyme disease, 85, 100 lymphocyte cell biology, 111 lymphoma, 124	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264 micronutrients, 30, 37, 78, 98, 133, 139, 154 Middle East Hypertension Initiative, 209 migration, 135, 136–137, 140–141, 235, 236–237, 240 miltefosine, 87 minorities health, 28–29 training grants, 50–51 mite allergens, 77 molecular regulation, 240 molecular biology, 66, 112–113, 166, 168,	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127 nasopharyngeal implantation of radium, 125 natural products, cancer therapy, 119 needle-stick injuries, 44 Nef protein, 98 Neisseria gonorrhoeae, 102, 105, 106 nelfinavir, 81, 99 nephropathy, 173 nerve fibers, severed, 241 nerve growth factor, 112, 150 neural control, 245
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71 lower-leg ulcers, chronic, 109 lung cancer, 122, 123, 124 disease, 16–17, 193, 212 morphogenesis, injury, and repair, 212 Lutzomyia, 80, 105 Lyme disease, 85, 100 lymphocyte cell biology, 111 lymphoma, 124 M Macaca spp., 256–257	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264 micronutrients, 30, 37, 78, 98, 133, 139, 154 Middle East Hypertension Initiative, 209 migration, 135, 136–137, 140–141, 235, 236–237, 240 miltefosine, 87 minorities health, 28–29 training grants, 50–51 mite allergens, 77 molecular regulation, 240 molecular biology, 66, 112–113, 166, 168, 174, 180, 198, 199, 200, 240, 244	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127 nasopharyngeal implantation of radium, 125 natural products, cancer therapy, 119 needle-stick injuries, 44 Nef protein, 98 Neisseria gonorrhoeae, 102, 105, 106 nelfinavir, 81, 99 nephropathy, 173 nerve fibers, severed, 241 nerve growth factor, 112, 150 neural control, 245 neurobiology, 7, 73, 148, 237, 240
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71 lower-leg ulcers, chronic, 109 lung cancer, 122, 123, 124 disease, 16–17, 193, 212 morphogenesis, injury, and repair, 212 Lutzomyia, 80, 105 Lyme disease, 85, 100 lymphocyte cell biology, 111 lymphoma, 124 M Macaca spp., 256–257 macromolecular structure, 260	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264 micronutrients, 30, 37, 78, 98, 133, 139, 154 Middle East Hypertension Initiative, 209 migration, 135, 136–137, 140–141, 235, 236–237, 240 miltefosine, 87 minorities health, 28–29 training grants, 50–51 mite allergens, 77 molecular regulation, 240 molecular biology, 66, 112–113, 166, 168, 174, 180, 198, 199, 200, 240, 244 molecular biophysics, 146–147	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127 nasopharyngeal implantation of radium, 125 natural products, cancer therapy, 119 needle-stick injuries, 44 Nef protein, 98 Neisseria gonorrhoeae, 102, 105, 106 nelfinavir, 81, 99 nephropathy, 173 nerve fibers, severed, 241 nerve growth factor, 112, 150 neural control, 245 neurobiology, 7, 73, 148, 237, 240 neurochemistry, 240
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71 lower-leg ulcers, chronic, 109 lung cancer, 122, 123, 124 disease, 16–17, 193, 212 morphogenesis, injury, and repair, 212 Lutzomyia, 80, 105 Lyme disease, 85, 100 lymphocyte cell biology, 111 lymphoma, 124 M Macaca spp., 256–257 macromolecular structure, 260 macrophages, 112	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264 micronutrients, 30, 37, 78, 98, 133, 139, 154 Middle East Hypertension Initiative, 209 migration, 135, 136–137, 140–141, 235, 236–237, 240 miltefosine, 87 minorities health, 28–29 training grants, 50–51 mite allergens, 77 molecular regulation, 240 molecular biology, 66, 112–113, 166, 168, 174, 180, 198, 199, 200, 240, 244 molecular biophysics, 146–147 molecular clocks, 63 molecular genetics, 67, 149, 198, 239, 256 molecular growth regulation, 149	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127 nasopharyngeal implantation of radium, 125 natural products, cancer therapy, 119 needle-stick injuries, 44 Nef protein, 98 Neisseria gonorrhoeae, 102, 105, 106 nelfinavir, 81, 99 nephropathy, 173 nerve fibers, severed, 241 nerve growth factor, 112, 150 neural control, 245 neurobiology, 7, 73, 148, 237, 240 neurochemistry, 240 neurocysticercosis, 83
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71 lower-leg ulcers, chronic, 109 lung cancer, 122, 123, 124 disease, 16–17, 193, 212 morphogenesis, injury, and repair, 212 Lutzomyia, 80, 105 Lyme disease, 85, 100 lymphocyte cell biology, 111 lymphoma, 124 M Macaca spp., 256–257 macromolecular structure, 260 macrophages, 112 Mad, 138	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264 micronutrients, 30, 37, 78, 98, 133, 139, 154 Middle East Hypertension Initiative, 209 migration, 135, 136–137, 140–141, 235, 236–237, 240 miltefosine, 87 minorities health, 28–29 training grants, 50–51 mite allergens, 77 molecular regulation, 240 molecular biology, 66, 112–113, 166, 168, 174, 180, 198, 199, 200, 240, 244 molecular biophysics, 146–147 molecular clocks, 63 molecular genetics, 67, 149, 198, 239, 256	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127 nasopharyngeal implantation of radium, 125 natural products, cancer therapy, 119 needle-stick injuries, 44 Nef protein, 98 Neisseria gonorrhoeae, 102, 105, 106 nelfinavir, 81, 99 nephropathy, 173 nerve fibers, severed, 241 nerve growth factor, 112, 150 neural control, 245 neurobiology, 7, 73, 148, 237, 240 neurochemistry, 240 neurocysticercosis, 83 neurodegenerative diseases, 214–215
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71 lower-leg ulcers, chronic, 109 lung cancer, 122, 123, 124 disease, 16–17, 193, 212 morphogenesis, injury, and repair, 212 Lutzomyia, 80, 105 Lyme disease, 85, 100 lymphocyte cell biology, 111 lymphoma, 124 M Macaca spp., 256–257 macromolecular structure, 260 macrophages, 112 Mad, 138 malacology, 82 malaria, 29, 44, 54, 79– 85passim, 88–96passim, 102, 105, 124, 250, 256	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264 micronutrients, 30, 37, 78, 98, 133, 139, 154 Middle East Hypertension Initiative, 209 migration, 135, 136–137, 140–141, 235, 236–237, 240 miltefosine, 87 minorities health, 28–29 training grants, 50–51 mite allergens, 77 molecular regulation, 240 molecular biology, 66, 112–113, 166, 168, 174, 180, 198, 199, 200, 240, 244 molecular biophysics, 146–147 molecular clocks, 63 molecular genetics, 67, 149, 198, 239, 256 molecular growth regulation, 149 molecular medicine, 244	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127 nasopharyngeal implantation of radium, 125 natural products, cancer therapy, 119 needle-stick injuries, 44 Nef protein, 98 Neisseria gonorrhoeae, 102, 105, 106 nelfinavir, 81, 99 nephropathy, 173 nerve fibers, severed, 241 nerve growth factor, 112, 150 neural control, 245 neurobiology, 7, 73, 148, 237, 240 neurochemistry, 240 neurocysticercosis, 83 neurodegenerative diseases, 214–215 neuroendocrinology, 137, 174 neuroepidemiology, 64, 65, 243–244 neurogenetics, 240
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71 lower-leg ulcers, chronic, 109 lung cancer, 122, 123, 124 disease, 16–17, 193, 212 morphogenesis, injury, and repair, 212 Lutzomyia, 80, 105 Lyme disease, 85, 100 lymphocyte cell biology, 111 lymphoma, 124 M Macaca spp., 256–257 macromolecular structure, 260 macrophages, 112 Mad, 138 malacology, 82 malaria, 29, 44, 54, 79– 85passim, 88–96passim, 102, 105, 124, 250, 256 cerebral, 91–92, 100, 106	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264 micronutrients, 30, 37, 78, 98, 133, 139, 154 Middle East Hypertension Initiative, 209 migration, 135, 136–137, 140–141, 235, 236–237, 240 miltefosine, 87 minorities health, 28–29 training grants, 50–51 mite allergens, 77 molecular regulation, 240 molecular biology, 66, 112–113, 166, 168, 174, 180, 198, 199, 200, 240, 244 molecular biophysics, 146–147 molecular clocks, 63 molecular genetics, 67, 149, 198, 239, 256 molecular growth regulation, 149 molecular medicine, 244 molecular neurobiology, 73	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127 nasopharyngeal implantation of radium, 125 natural products, cancer therapy, 119 needle-stick injuries, 44 Nef protein, 98 Neisseria gonorrhoeae, 102, 105, 106 nelfinavir, 81, 99 nephropathy, 173 nerve fibers, severed, 241 nerve growth factor, 112, 150 neural control, 245 neurobiology, 7, 73, 148, 237, 240 neurochemistry, 240 neurocysticercosis, 83 neurodegenerative diseases, 214–215 neuroendocrinology, 137, 174 neuroepidemiology, 64, 65, 243–244 neurogenetics, 240 neuroinformatics, 233–234, 238
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71 lower-leg ulcers, chronic, 109 lung cancer, 122, 123, 124 disease, 16–17, 193, 212 morphogenesis, injury, and repair, 212 Lutzomyia, 80, 105 Lyme disease, 85, 100 lymphocyte cell biology, 111 lymphoma, 124 M Macaca spp., 256–257 macromolecular structure, 260 macrophages, 112 Mad, 138 malacology, 82 malaria, 29, 44, 54, 79– 85passim, 88–96passim, 102, 105, 124, 250, 256 cerebral, 91–92, 100, 106 children, 85, 90	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264 micronutrients, 30, 37, 78, 98, 133, 139, 154 Middle East Hypertension Initiative, 209 migration, 135, 136–137, 140–141, 235, 236–237, 240 miltefosine, 87 minorities health, 28–29 training grants, 50–51 mite allergens, 77 molecular regulation, 240 molecular biology, 66, 112–113, 166, 168, 174, 180, 198, 199, 200, 240, 244 molecular biophysics, 146–147 molecular clocks, 63 molecular genetics, 67, 149, 198, 239, 256 molecular growth regulation, 149 molecular hematology, 176 molecular neurobiology, 73 molecular neurogenetics, 239	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127 nasopharyngeal implantation of radium, 125 natural products, cancer therapy, 119 needle-stick injuries, 44 Nef protein, 98 Neisseria gonorrhoeae, 102, 105, 106 nelfinavir, 81, 99 nephropathy, 173 nerve fibers, severed, 241 nerve growth factor, 112, 150 neural control, 245 neurobiology, 7, 73, 148, 237, 240 neurochemistry, 240 neurocysticercosis, 83 neurodegenerative diseases, 214–215 neuroendocrinology, 137, 174 neuroepidemiology, 64, 65, 243–244 neurogenetics, 240 neuroinformatics, 233–234, 238 neurological disorders, 20–21, 241–245
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71 lower-leg ulcers, chronic, 109 lung cancer, 122, 123, 124 disease, 16–17, 193, 212 morphogenesis, injury, and repair, 212 Lutzomyia, 80, 105 Lyme disease, 85, 100 lymphocyte cell biology, 111 lymphoma, 124 M Macaca spp., 256–257 macromolecular structure, 260 macrophages, 112 Mad, 138 malacology, 82 malaria, 29, 44, 54, 79– 85passim, 88–96passim, 102, 105, 124, 250, 256 cerebral, 91–92, 100, 106 children, 85, 90 recombinant viruses, 99, 101	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264 micronutrients, 30, 37, 78, 98, 133, 139, 154 Middle East Hypertension Initiative, 209 migration, 135, 136–137, 140–141, 235, 236–237, 240 miltefosine, 87 minorities health, 28–29 training grants, 50–51 mite allergens, 77 molecular regulation, 240 molecular biology, 66, 112–113, 166, 168, 174, 180, 198, 199, 200, 240, 244 molecular biophysics, 146–147 molecular clocks, 63 molecular genetics, 67, 149, 198, 239, 256 molecular growth regulation, 149 molecular hematology, 176 molecular neurobiology, 73 molecular neurophysiology, 147	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127 nasopharyngeal implantation of radium, 125 natural products, cancer therapy, 119 needle-stick injuries, 44 Nef protein, 98 Neisseria gonorrhoeae, 102, 105, 106 nelfinavir, 81, 99 nephropathy, 173 nerve fibers, severed, 241 nerve growth factor, 112, 150 neural control, 245 neurobiology, 7, 73, 148, 237, 240 neurochemistry, 240 neurocysticercosis, 83 neurodegenerative diseases, 214–215 neuroendocrinology, 137, 174 neuroepidemiology, 64, 65, 243–244 neurogenetics, 240 neuroinformatics, 233–234, 238 neurological disorders, 20–21, 241–245 neurology, medical, 243
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71 lower-leg ulcers, chronic, 109 lung cancer, 122, 123, 124 disease, 16–17, 193, 212 morphogenesis, injury, and repair, 212 Lutzomyia, 80, 105 Lyme disease, 85, 100 lymphocyte cell biology, 111 lymphoma, 124 M Macaca spp., 256–257 macromolecular structure, 260 macrophages, 112 Mad, 138 malacology, 82 malaria, 29, 44, 54, 79– 85passim, 88–96passim, 102, 105, 124, 250, 256 cerebral, 91–92, 100, 106 children, 85, 90 recombinant viruses, 99, 101 malformations, babies delivered by	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264 micronutrients, 30, 37, 78, 98, 133, 139, 154 Middle East Hypertension Initiative, 209 migration, 135, 136–137, 140–141, 235, 236–237, 240 miltefosine, 87 minorities health, 28–29 training grants, 50–51 mite allergens, 77 molecular regulation, 240 molecular biology, 66, 112–113, 166, 168, 174, 180, 198, 199, 200, 240, 244 molecular biophysics, 146–147 molecular clocks, 63 molecular genetics, 67, 149, 198, 239, 256 molecular growth regulation, 149 molecular hematology, 176 molecular neurobiology, 73 molecular neurobiology, 73 molecular neuroscience, 236	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127 nasopharyngeal implantation of radium, 125 natural products, cancer therapy, 119 needle-stick injuries, 44 Nef protein, 98 Neisseria gonorrhoeae, 102, 105, 106 nelfinavir, 81, 99 nephropathy, 173 nerve fibers, severed, 241 nerve growth factor, 112, 150 neural control, 245 neurobiology, 7, 73, 148, 237, 240 neurochemistry, 240 neurocysticercosis, 83 neurodegenerative diseases, 214–215 neuroendocrinology, 137, 174 neuroepidemiology, 64, 65, 243–244 neurogenetics, 240 neuroinformatics, 233–234, 238 neurological disorders, 20–21, 241–245 neurology, medical, 243 neuropharmacology, 236, 240
damage, alcohol induced, 70–71 disease, 173, 215 London Gin Epidemic, 71 lower-leg ulcers, chronic, 109 lung cancer, 122, 123, 124 disease, 16–17, 193, 212 morphogenesis, injury, and repair, 212 Lutzomyia, 80, 105 Lyme disease, 85, 100 lymphocyte cell biology, 111 lymphoma, 124 M Macaca spp., 256–257 macromolecular structure, 260 macrophages, 112 Mad, 138 malacology, 82 malaria, 29, 44, 54, 79– 85passim, 88–96passim, 102, 105, 124, 250, 256 cerebral, 91–92, 100, 106 children, 85, 90 recombinant viruses, 99, 101	methamphetamine, 15, 183 metronidazole, 103 microbicides, 91, 98–101 <i>passim</i> , 133 microbioloy, 263–264 micronutrients, 30, 37, 78, 98, 133, 139, 154 Middle East Hypertension Initiative, 209 migration, 135, 136–137, 140–141, 235, 236–237, 240 miltefosine, 87 minorities health, 28–29 training grants, 50–51 mite allergens, 77 molecular regulation, 240 molecular biology, 66, 112–113, 166, 168, 174, 180, 198, 199, 200, 240, 244 molecular biophysics, 146–147 molecular clocks, 63 molecular genetics, 67, 149, 198, 239, 256 molecular growth regulation, 149 molecular hematology, 176 molecular neurobiology, 73 molecular neurophysiology, 147	Nagasaki, 126 naltrexone, 186 nasopharyngeal cancer, 126–127 nasopharyngeal implantation of radium, 125 natural products, cancer therapy, 119 needle-stick injuries, 44 Nef protein, 98 Neisseria gonorrhoeae, 102, 105, 106 nelfinavir, 81, 99 nephropathy, 173 nerve fibers, severed, 241 nerve growth factor, 112, 150 neural control, 245 neurobiology, 7, 73, 148, 237, 240 neurochemistry, 240 neurocysticercosis, 83 neurodegenerative diseases, 214–215 neuroendocrinology, 137, 174 neuroepidemiology, 64, 65, 243–244 neurogenetics, 240 neuroinformatics, 233–234, 238 neurological disorders, 20–21, 241–245 neurology, medical, 243

neuropsychology, 59, 62–63, 240	phantom, 243	probiotic mixture, 141
neuroscience, 59, 62–63, 239, 240, 244–245	Pan American Hypertension Initiative,	program support, 4
neurosensory mechanisms, 167	207–208	prostate, 62
neurotrophins, 48, 150	pancreas, 166, 171, 174	prostate cancer, 123, 124, 127, 134, 225
neurovirulence factor, 83	parasitic diseases, 9, 77–107 <i>passim</i>	protease inhibitors, 99
nevirapine, 88, 106	variation and infectivity, 92	protein, 55, 146, 179, 202
Niemann-Pick disease, 174	parathyroid, 175	data bank, 203
nitric oxide, 49, 85	parenting, 142	proteoglycans, 210, 212
noma, 155	Parkinson's disease, 225	proton radiation, 128–129
non-Hodgkin's lymphoma, 248	PCBs, 125, 192, 193	protozoan sialidases, 104
nonoxynol 9, 81, 89, 98	PDQ, 116–117	psoriasis, 109
Notch 1, 137	pemphigus foliaceus, 109–110	psychiatric disease. <i>See</i> mental health
nuclear medicine, 264–265	pentoxifylline, 90	psychoactive drugs, metabolism, 236
nucleic acids, 180	peptides, 258	psychological development, 61
nucleotide polymorphisms, 18	perfluoroalkylpyrimidines, 14	psychology, aging, 59
nursing, 21–22, 247–248, 265	perinatology, 56–57, 146	psychopathology, 235–236, 237
nutrition, 73, 91, 136, 138, 140,	periodontal disease, 158, 159	psychopharmacology, 238
171–176 <i>passim</i>	perlecan, 164	PTEN, 163
171 170риззии	peroxidase, 217	pulmonary disease, 215, 218
0	personality, 67, 235	chronic obstructive, 211, 212
O-150 antigen, 94	pertussis vaccine, 88	pulmonary hypertension, 31
obesity, 256	pesticides, 123, 124, 192	paintonary hypertension, or
obsessive-compulsive disorder, 239	PET imaging, schizophrenia, 238	Q
occupational health, 42–44, 56, 137, 194	pharmacology, 202, 240	quality assurance, 264
occupational risk, cancer, 123, 124, 126,	pharmacy, 265–266	quanty assurance, 201
127, 128	pharyngeal cancer, 166–167	R
olfactory proteins and neurons, 151–152	Phlebotomus spp., 88	radiation effects, 125, 126, 128
Oligorhyzomys microtis, 95	photoreceptor synapses, 200	radiology, diagnostic, 128–129, 264
Onchocerca volvulus, 83, 91, 94, 100	phototherapy, 135, 138	rainforests, biodiversity, 38
onchocerciasis, 80, 95	phthalates, 192	RANTES, 100
onchodermatitis, 83	physical biology, 149–150	rare diseases, 30–31
oncogenes, 123, 167	physiology, 175–176, 202	Rattus spp., 96
oophorectomy, 128	Pima Indians, 176	receptors, 174
opioids, 184–185, 192	plants, analysis, 91, 94, 100, 119	recombination-activating gene, 105
oral cancer, 160, 166–167	plaque, 158	refractive error, 197–198
oral clefts, 225–226	Plasmodium spp., 79–83passim, 87, 90, 92,	refugees. See migration
oral health, 155, 161, 164, 165–166	95. 101. 102. 105	regeneration, craniofacial, 163–164
see also craniofacial health	platelet adhesion, 49	registries
organochlorines, 193	pneumococcal conjugate vaccine, 85	birth, 191
Oropouche virus, 96	Pneumocystis carinii, 94, 104	cancer, 116, 124, 127, 128
orphanin FQ, 184	pollution, 123, 192	Fanconi anemia, 255
orphans, AIDS, 231–232	polycystic ovary syndrome, 131–132	skeletal dysplasia, 133
oseltamivir, 105	population, 44, 45, 60–61, 138–139	rehabilitation medicine, 266
osteoarticular disease, 59–60	population-based medicine, 31	relapsing fever, 81
osteogenesis imperfecta, 31, 146	population-based studies, 1–2	religious healing, 235
osteonectin, 163	positron emission tomography, 266	renal carcinoma, 12, 120
osteoporosis, 72	praziquantel, 84	reperfusion injury, 218
otitis media, 84, 151	preeclampsia, 132	reproduction, 138, 145–146
ovarian cancer, 128	pregnancy, 90, 102, 134, 140, 166, 235	reproductive sciences, 133
oxfendazole, 90, 95	alcohol use and, 70, 71	reproductive system, male, 62
oxygen, 173, 216	lead, 16, 191	research
, , ,	see also HIV transmission, mother-to-child	awards, 4
P	prenatal care, 15, 134	resources, 67, 255–257
p24 antigen, 101	primary care, 72, 160, 228	risks, 32
p53, 124, 160, 191–192	primates, 256–257	respiratory syncytial virus, 91
pain, 160–161, 161–162, 167	print information, cancer, 117, 129	retinoid, 124

retroviral co-infection, 78–79	spectroscopy, 179	toxoplasmosis, 84, 197
rhesus monkeys, 257	speech, 243	trachoma, 77
rheumatism, 110–111	spermatogonia, 142	traditional medicine, 253
Rho A/B, 215	spermicides, 133	training, 27, 188, 194, 250
ribosomes, crystallography, 16, 202	spinal cord injury, 20–21, 241	transferrins, recombinant, 172
Rickettsia spp., 93, 96	sporotrichosis, 96	transfusion medicine, 266
rifampacin, 104	squamous cell carcinoma, 123-124	transgenic mice, 212
risk behavior, 26	SRHEP, 99	transplantation, 214–215
ritonavir, 81	statistics, 12, 144-145	trauma, 32, 228, 236–237
rodents, viruses and, 105	cancer, 121, 129	see also injury; violence
rotavirus, 141	mechanical models, 179	Trichomonas, 90, 173
	sterilization, 135	trimethylaminuria, 31
S	steroid-catecholamine interactions, 237	trophic factors, 214
Saccharomyces cerevisiae, 148	steroid hormones, 180–181	truck drivers, male, 89–90
salivary glands, 163, 164	stomach cancer, 126	<i>Trypanosoma</i> spp., 77, 85, 86, 104
Salmonella typhi, 100	Streptococcus spp., 80, 81, 89, 96, 106, 158	trypsin, 149
sand flies, 83, 88, 105	stress, 72, 137, 235, 236, 237	tuberculosis, 3, 37–38, 78, 79, 83, 87, 90,
Schistosoma spp., 9, 77, 84, 89, 96	stroke, 20–21, 241–245, 244	93, 94, 97–104 <i>passim</i> , 219
schistosomiasis, 79, 84, 90, 96	death rates, 208, 209	tumor necrosis factor, 9–11, 86, 87, 88
schizophrenia, 235–240passim, 255	Strongyloides, 80	tumor-suppressor protein, 66, 163
Schizosaccharomyces pombe, 148	structural biology, 110, 113, 149–150, 168	twins
scholars in residence, 48–49	surveys, vision, 198	aging, 61, 62
scientific review, 22–23, 261	survivors of disasters, 228	alcohol and, 70, 71
scientist awards, 4	synchrotron-based macromolecular	typhoid fever, 100
screening instruments, alcohol use, 71–72	crystallography research, 257	typhus, 96
secretory physiology, 165	, 01,	71
seroconversion, HIV, 106	Т	U
sertraline, 186	Taenia solium, 95	urologic diseases, 173
sex workers, 94–98passim, 159	tamoxifen, 124, 128	,
condom use, 97	taste receptors, genes, 13, 154	V
sexually transmitted diseases, 18–20, 26,	T cells, 66, 81, 87, 94, 99, 104	vaccines, 77-88passim, 94, 100, 133, 141,
81, 87, 89, 95, 100–103 <i>passim</i> , 125	technical assistance, 188	147–148, 165–166, 171, 256
HIV/AIDS and, 86, 90, 231	teenagers, 187	hepatitis, 81, 165–166
Shigella, 81, 141, 148	TELESYNERGY, 258	HIV, 37, 79–84passim, 89, 98–104passim,
sialuria, 146	telomerase, 62	166
sickle cell disease, 248	telomere, 192	influenza, 82, 97, 100
signal transduction, 111, 163	temporomandibular joint, 161	malaria, 80, 85, 87, 92, 99, 100
simian immunodeficiency virus, 81, 85	testicular cancer, 128	measles, 85
Simulium damnosum senso lato, 83	tetanus toxins, 148	vascular disease, 170
single nucleotide polymorphisms, 18	β-thalassemia, 176	vascular epithelial growth factor, 166
skeletal diseases, 164–165	therapeutics	vasectomy, 134
skeletal dysplasia, 140, 164	developmental, 118–119	vector biology, 80–106passim
registry, 133	experimental, 243	Vibrio cholerae, 78, 95, 247
skin biology, 112	thiacetazone, 104	violence, 134, 143, 185
skin and bone biology, 110	thymosin, 163	domestic, 235, 247
skin diseases, 9–11, 91, 109–113	thyroid cancer, 48–49, 126, 128	see also injury; trauma
sleep, 212–213, 221, 256	tic disorders, 239	viral diseases, 77–78, 82–107passim
smoking, 15, 126, 137, 156, 164, 183	ticks, 85	virology, 244
social interactions, 26	tissue engineering, 161	viruses, 147, 260
social networks, 28, 143	tissue microarray technology, 225	see also particular virus
social sciences, 31–32, 61	tobacco. See smoking	vision, 14–15, 37, 91, 97, 100, 138,
socioeconomics, 28, 135, 136, 142	α-tocopherol, 123	197–200
see also economics	torture, 229	vitamins, 103
socio-environmental studies, 240	toxicity criteria, 118	vitamin supplements, 199
software, 257	toxicology, 192	vitiligo, 109
specialized centers of research programs, 213	Toxoplasma, 80	volunteers, 56, 57

W

walking, 65
women, 27–28, 70, 97, 211, 217
aging, 65, 66
empowerment, 135, 139–140
heart disease and stroke, 206, 209
see also HIV transmission, mother-to-child
wound repair, 163
Wuchereria spp., 78, 86, 90

X

Xenopus, 151 X-linked adrenoleukodystrophy, 30–31

Υ

yeast, structure, 16 yellow fever, 96, 102 *Yersinia pestis,* 100

Z

zanimivir, 104 zebra fish, 172–173 zidovudine, 4, 36–37, 86, 98, 103, 134, 143 zinc, 29, 56, 139 zoonoses, 82, 95